SAN DIEGO, CA--(Marketwired - August 30, 2016) - Aegis Therapeutics LLC announced today that it has been awarded Hong Kong Patent No. HK1164059 providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster than the currently marketed non-injectable sumatriptan products. For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.
The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.
Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis' licensees include seven of the top 10 largest pharmaceutical companies and two of the top 10 largest multinational generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than seventy-five issued and pending drug formulation patents covering noninvasive delivery and stabilization of biotherapeutics, biosimilars, and small-molecule drugs.
Read more: http://www.marketwired.com/press-release/aegis-awarded-9th-patent-for-fast-acting-migraine-nasal-spray-treatment-2154203.htm